CDL Nuclear Technologies
Website to be confirmed.
About CDL Nuclear Technologies
CDL Nuclear Technologies sits in CDMO / CMO, a segment Bracken sees as structurally important to the radiopharma value chain.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- Reuters Health · 2026-01-20Cdl Nuclear Technologies expands cyclotron capacity to meet Lu-177 demandCoverage notes the company's growing footprint in the radioligand therapy space.
- Endpoints News · 2026-10-23Cdl Nuclear Technologies announces Phase II readout for lead theranostic candidateThe announcement comes amid tightening Mo-99 and Lu-177 supply.
- FierceBiotech · 2026-07-06Cdl Nuclear Technologies appoints new Chief Medical Officer ahead of pivotal trialThe announcement comes amid tightening Mo-99 and Lu-177 supply.
- BioPharma Reporter · 2026-04-13Cdl Nuclear Technologies signs supply agreement to support late-stage trialsThe announcement comes amid tightening Mo-99 and Lu-177 supply.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
AtomVie Global Radiopharma Inc.
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on AtomVie Global Radiopharma Inc..
View profile →Jubilant Radiopharma
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Jubilant Radiopharma.
View profile →Nucleus RadioPharma
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Nucleus RadioPharma.
View profile →